Published in final edited form as:

ACS Infect Dis. 2018 March 09; 4(3): 325–336. doi:10.1021/acsinfecdis.7b00152.

Structure-Based Analysis of Boronic Acids as Inhibitors of *Acinetobacter*-Derived Cephalosporinase-7, a Unique Class C β Lactamase

Alexandra A. Bouza^{†,‡}, Hollister C. Swanson^{†,‡}, Kali A. Smolen[†], Alison L. VanDine[†], Magdalena A. Taracila^{§,||}, Chiara Romagnoli[‡], Emilia Caselli[‡], Fabio Prati[‡], Robert A. Bonomo^{*,§,||}, Rachel A. Powers^{*,†}, and Bradley J. Wallar^{*,†}

[†]Department of Chemistry, Grand Valley State University, 1 Campus Drive, Allendale, Michigan 49401, United States

[‡]Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy

[§]Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106, United States

^{||}Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States

Abstract

Acinetobacter baumannii is a multidrug resistant pathogen that infects more than 12 000 patients each year in the US. Much of the resistance to β -lactam antibiotics in *Acinetobacter spp.* is mediated by class C β -lactamases known as *Acinetobacter*-derived cephalosporinases (ADCs). ADCs are unaffected by clinically used β -lactam-based β -lactamase inhibitors. In this study, five boronic acid transition state analog inhibitors (BATSI) were evaluated for inhibition of the class C cephalosporinase ADC-7. Our goal was to explore the properties of BATSI designed to probe the R1 binding site. K_i values ranged from low micromolar to subnanomolar, and circular dichroism (CD) demonstrated that each inhibitor stabilizes the β -lactamase-inhibitor complexes. Additionally, X-ray crystal structures of ADC-7 in complex with five inhibitors were determined (resolutions from 1.80 to 2.09 Å). In the ADC-7/CR192 complex, the BATSI with the lowest K_i (0.45 nM) and greatest T_m (+9 °C), a trifluoromethyl substituent, interacts with Arg340. Arg340

*Corresponding Authors: robert.bonomo@va.gov. Phone: 216-791-3800 ext 4645 (R.A.B.). powersra@gvsu.edu. Phone: 616-331-2853 (R.A.P.). wallarb@gvsu.edu. Phone: 616-331-3807 (B.J.W.).

#A.A.B. and H.C.S. contributed equally to the manuscript.

ORCID

Robert A. Bonomo: 0000-0002-3299-894X

Rachel A. Powers: 0000-0002-9968-8284

Author Contributions

C.R., E.C., and F.P. synthesized all of the BATSI compounds. M.A.T. and R.A.B. performed microbiological assays, circular dichroism, and kinetics. R.A.P., B.J.W., A.A.B., H.C.S., K.A.S., and A.L.V. performed kinetics and determined all of the crystal structures. All authors have contributed to the manuscript and have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

is unique to ADCs and may play an important role in the inhibition of ADC-7. The ADC-7/BATSI complexes determined in this study shed light into the unique recognition sites in ADC enzymes and also offer insight into further structure-based optimization of these inhibitors.

Graphical Abstract

Keywords

β -lactamase; cephalosporinase; boronic acid; transition state analog inhibitors; *Acinetobacter*; ADC-7

Since the discovery of penicillin in the late 1920s, antibiotic resistance has been a major threat to human health.¹ During the past decade, resistance to all classes of β -lactam antibiotics (penicillins, cephalosporins, carbapenems) among *Acinetobacter baumannii* has considerably increased.^{2–6} Although there are many mechanisms that contribute to the resistance, such as efflux pumps and porins, β -lactamases are the primary cause of resistance to β -lactam antimicrobials.¹

β -Lactamases function by hydrolyzing the amide bond in the lactam ring of β -lactam antibiotics, preventing β -lactam inhibition of its original cellular targets, the transpeptidases.^{2,7} A significant portion of the β -lactamase-mediated resistance in *Acinetobacter* results from a unique family of class C enzymes, the *Acinetobacter*-derived cephalosporinases (ADCs).^{2,8,9} ADCs are chromosomally encoded β -lactamases responsible for resistance to cephalosporin antibiotics such as cephalexin.⁸ Specifically, ADC-7 was identified in a clinical isolate of *A. baumannii* that exhibited extended-spectrum activity against numerous β -lactams.⁸ In addition, ADCs are unique from other class C β -lactamases as they possess several distinct active site residues.¹⁰ These evolutionarily induced sequence differences in ADC-7 serve as a potential explanation for the enzyme's plasticity in catalyzing multiple cephalosporins and may aid in targeted drug discovery efforts.¹¹

One way to circumvent β -lactamase-mediated resistance is using β -lactamase inhibitors (BLIs) (Figure 1). Current commercially available BLIs, like sulbactam and clavulanic acid, are prescribed in combination therapies with a partner β -lactam antibiotic.¹¹ Unfortunately, these BLIs are themselves β -lactams, and bacteria are able to develop resistance rapidly

against these chemically similar molecules.¹² Moreover, these BLIs have been shown to be ineffective against *Acinetobacter* spp., with relatively high K_i values (500–4000 μM) for clinically used BLIs.⁸ The design of novel BLIs is essential to overcome cephalosporinase-mediated resistance in *Acinetobacter* and its overwhelming clinical threat.¹³

Novel non- β -lactam-based BLIs have been identified and characterized, including the phosphonates,¹⁴ hydroxamates,¹⁵ and diazabicyclooctanes (DBOs).^{16,17} In 2015, the FDA approved the combination therapy known as Avycaz, which pairs the third-generation cephalosporin ceftazidime with the novel DBO inhibitor avibactam.¹⁸ Another class of novel BLIs are the boronic acid transition state analog inhibitors (BATSI) that have long been known to inhibit class A and C β -lactamases (Figure 1).^{10,19,20,12} Previous work in our group suggested that BATSI offer excellent potential as inhibitors of ADC enzymes in *A. baumannii*, specifically ADC-7, with K_i values in the nanomolar range.¹⁰ Additionally, the X-ray crystal structure of ADC-7 in complex with the BATSI S02030 (Protein Data Bank, PDB 4U0X¹⁰) provided insight into ways this series might be optimized.

In the present study, a select group of five different BATSI (4 from the CR series and 1 from the S series) were characterized via X-ray crystallography and kinetic analysis and shown to bind with high affinity and inhibit ADC-7 activity. These BATSI were chosen due to their effectiveness in microbiological disc susceptibility assays, as well as their ability to probe interactions between active site residues and the R1 inhibitor group, which is meant to resemble the R1 side chains of β -lactam antibiotics (Figure 1A,C). Canonical binding sites identified in related class C β -lactamase/BATSI complexes were also observed in these ADC-7 complexes. However, several unique interactions and binding sites were identified in these newly determined structures. One such binding site is comprised of Asn213 and Ser317 and serves to bind the distal carboxylate and/or tetrazole groups to the CR inhibitor series. The optimization of these BATSI will aid in mapping the ADC-7 active site for inhibitor “hot spot” binding sites and contribute to our understanding of β -lactamase mediated antibiotic resistance in *Acinetobacter*.

RESULTS AND DISCUSSION

Microbiology, Thermal Stability, and Kinetics

In order to assess the potency of the inhibitors in whole cells, MIC and disc susceptibility assays were performed using *E. coli* DH10B expressing *wtADC-7* and the R340A variant. When the compounds were paired with the β -lactam ceftazidime (10 μg of CAZ and 10 μg of BATSI), the disk zone sizes increased from 12 mm for CAZ alone to 20–26 mm for all the compounds in the CR series (Table 1). When the sulfonamide group present in the CR series compounds is replaced by triazole (S series compound S06017), the zone size decreased to 15 mm. A similar trend was observed when MICs were performed. Using a fixed concentration of the BATSI (4 $\mu\text{g}/\text{mL}$) and varying CAZ concentrations, the MIC values were shown to decrease from 64 $\mu\text{g}/\text{mL}$ to lower than 2 $\mu\text{g}/\text{mL}$ (0.5 $\mu\text{g}/\text{mL}$ for CR161, 1 $\mu\text{g}/\text{mL}$ for CR167 and CR157, and 2 $\mu\text{g}/\text{mL}$ for CR192) (Table 2). Consistent with the trend of the DSA studies, the MIC for S06017 was much higher (16 $\mu\text{g}/\text{mL}$) than compounds in the CR series. In the multidrug resistant (MDR) clinical strain, from which ADC-7 was initially cloned, we also see a reduction of MIC values from >64 to 8 $\mu\text{g}/\text{mL}$ for

the CR series and to 16 $\mu\text{g/mL}$ for S06017. The reduction of MICs to 8 $\mu\text{g/mL}$ is most encouraging as the lack of permeability across the outer membrane of *A. baumannii* is a significant challenge in medicinal chemistry.¹⁰ Interestingly, the mutation at the distal site Asn213Ala preserved the MICs for most of the compounds. The interactions between the tetrazole and backbone atoms of the Ala residue are probably preserved and/or interactions with Ser317 compensate for the loss of Asn213 interactions. The MIC for CR192 in *E. coli* decreased from 2 to 1 $\mu\text{g/mL}$ for the Asn213Ala variant. Similar behavior was observed for CR192 with the Arg340Ala ADC-7 variant, but the MIC decrease is larger, 0.5 $\mu\text{g/mL}$. The Lys variant restored the MIC of the wild type. This may suggest that the tetrazole interactions with the distal site Asn213/Ser317 are more beneficial in terms of preserving the affinity and potency of the inhibitors when the mutations in the active site of the enzyme occur. With respect to position 340, the MICs for CR161 and CR157 do not change significantly with the mutations.

We observed that the thermal stability of the ADC-7 enzyme increases when complexed with BATSI (Figure 2). The variation in melting temperature is from 2 °C for S06017 and CR161 to 4 °C for CR157 and CR161 complexes. The larger variation is for the CR192/ADC-7 complex, which increases the melting temperature (T_m) by 9 °C (Table 3). The R340A and N213A mutations do not change the thermal stability of the enzyme, preserving the T_m of $\approx 61\text{--}62$ °C.

The binding affinity of ADC-7 for the five BATSIs was assessed using competition kinetics. The initial velocities were determined by utilizing nitrocefin (NCF) as a colorimetric indicator substrate. As shown in Table 3, all the BATSIs tested were effective inhibitors of ADC-7, with one K_i value, CR192, dropping into the subnanomolar range. The weakest binding BATSI, S06017, had a K_i of 6.11 μM . While each of the CR inhibitors bound to ADC-7 with high affinity, the best inhibitor was CR192, which had a K_i of 0.45 nM. The weakest binding BATSI in the CR series was CR167, which still had a relatively low K_i of 160 nM. The remaining two CR BATSIs tested, CR161 and CR157, possessed K_i values of 7.8 and 38 nM, respectively.

X-ray Crystal Structure of ADC-7/Inhibitor Complexes

Structure Determination—To characterize the specific active site interactions with the inhibitors, all five ADC-7/ BATSI complexes were determined via X-ray crystallography. The CR167, CR157, CR161, CR192, and S06017 complexes were determined to be 1.80, 2.06, 2.09, 2.03, and 1.93 Å, respectively. Each ADC-7/BATSI complex crystallized in the $P2_1$ space group with four monomers in the asymmetric unit (Table 4). The structure was determined via molecular replacement using the ADC-7 structure from *A. baumannii* (PDB 4U0T) with waters and ions removed.¹⁰ Inspection of the initial $F_o\text{--}F_c$ electron density maps contoured at 3σ demonstrated that each inhibitor was bound in the active sites of all four monomers comprising the asymmetric unit. For all structures, electron density for the inhibitors was contiguous with the $O\gamma$ atom of Ser64, indicative of the expected covalent attachment with the boron of the inhibitors (Figure 3). $F_o\text{--}F_c$ omit maps contoured at 3.0σ confirmed the presence of each inhibitor, their covalent attachments to Ser64, and the tetrahedral geometry about the boron which mimics the presumed transition state in β -

lactam hydrolysis. Unexpectedly, electron density maps of all five ADC-7/BATSI complexes revealed that the boronic acid O2 atom was modified with the addition of a covalently bound phosphate ion (Figure 3). Superposition of the four monomers of the asymmetric unit in each of the ADC-7/BATSI crystal structure shows that the inhibitor binds in nearly identical orientations in each site, with mean root-mean-square deviations (RMSDs) for superposition of all inhibitor atoms ranging from 0.8 Å for the CR157 complex to 0.5 Å for CR161, 0.6 Å for CR167 and S06017, and 0.7 Å for CR192. In all cases, thermal B factors are lowest for the B monomer. For simplicity, the B monomer is used as representative of all monomers.

Canonical Interactions—As expected, in every structure, the O1 hydroxyl groups of the BATSIs are bound in the oxyanion hole, hydrogen bonding with the main chain nitrogens of Ser64 and Ser315 and the main chain oxygen of Ser315 (Figure 4). The boronic acid O2 hydroxyl group is usually observed to form hydrogen bonds with Tyr150OH and a well-ordered water molecule, believed to represent the deacylating water. The interaction between the O2 and Tyr150 is maintained in the CR series of BATSIs but not in the S06017 structure. It is somewhat surprising that this interaction is still present in the CR series, given that the boronic acid O2 group has been covalently modified with a phosphate group. In the CR structures, the phosphate forms hydrogen bonds with approximately two or three water molecules as well as the hydroxyl group of Thr313. In the S06017 structure, the phosphate group is oriented to form hydrogen bonds with Tyr150. The presumed deacylating water is present in each structure, except it interacts with one of the phosphate oxygens, not the O2 hydroxyl.

The CR series of inhibitors replace the R1 amide found in the R1 side chains of β -lactams with a sulfonamide group. In the crystal structures, one of the sulfonyl oxygens mimics the amide oxygen by hydrogen bonding with the side chain amide nitrogens of Gln120 and Asn152 (Figure 5).²¹ However, the sulfonamide nitrogen does not hydrogen bond to the main chain carbonyl oxygen of Ser315, as the R1 amide nitrogen does in complexes with β -lactams.

Variable Interactions—Beyond the canonical interactions maintained with the core boronic acid group of the BATSIs, each of the inhibitors display interactions with the enzyme that are unique to their R1 groups. In contrast to the sulfonamide found in the R1 groups of the CR series, S06017 contains a triazole ring. Similar to the sulfonamide, the triazole ring also hydrogen bonds to the side chain amide nitrogens of both Gln120 and Asn152 (3.0–3.2 Å).

Following the sulfonamide, the CR series all contain a conjugated aryl ring in the R1 group of the inhibitors. The aryl rings of CR157, CR161, and CR192 all form edge-to-face π - π stacking interactions with Tyr222. The aryl ring of CR167 also interacts with Tyr222 although the interaction with this residue is a parallel displaced π - π stacking interaction (Figure 7).

The distal ends of the R1 groups of each of the BATSIs contain a negatively charged group, either a carboxylate (CR167, S06017) or a tetrazole group (CR157, CR161, CR192). The distal functional group of CR157, CR161, CR167, and CR192 all bind in a site formed by

Asn213 and Ser317 at the edge of the active site. The carboxylate/tetrazole groups form favorable hydrogen bonding interactions (between 2.8 and 3.2 Å) with the main chain nitrogen atoms of Asn213 and Ser317. A hydrogen bond is also formed between the tetrazole/carboxylate of CR157, CR192, and CR167 and the side chain O γ of Ser317 (~3.2 Å). The anionic tetrazole/ carboxylate groups also make hydrogen bonds with either one (CR157 and CR167) or two (CR161 and CR192) water molecules (Figure 5). Due to its shorter R1 group, the carboxylate of S06017 is unable to reach the distal Asn213/ Ser317 site. Instead, the S06017 carboxylate makes ionic interactions with Arg340 (2.8–3.1 Å). Unique to CR192, a distinct interaction between the trifluoromethyl group of the inhibitor and the side chain of Arg340 is observed (4.0 Å; Figure 6).

A combination of several functional assays with the X-ray crystal structures of five different ADC-7/BATSI complexes revealed important insight for targeting favorable interactions with the R1 binding site of ADC-7 cephalosporinase. Analysis of key interactions observed in the structures support the inhibition data obtained through kinetic studies.

Unexpectedly, in all the ADC-7/BATSI complexes, F_o–F_c difference electron density maps revealed a significant (>3 σ) peak that appeared to be covalently bonded with the O2 of the boronic acid. A phosphate group was modeled into these peaks, and the final structures support phosphorylation of the boronic acid O2 hydroxyl groups (Figure 3). The covalently attached phosphate is observed in all five of the ADC-7/BATSI complexes presented here. However, this modification was not observed in the structure of our first ADC-7/BATSI complex (PDB 4U0X; Figure 3).¹⁰ The main difference between the previously determined ADC-7/BATSI complex (S02030) and the ones presented here is that the original inhibitor also contained an R2 group (Figure 1C).¹⁰ The CR series BATSI from this study do not possess an R2 group. The presence of the R2 group may prevent phosphorylation of the O2 hydroxyl by occluding access to this functional group. The O2 phosphorylation may be a crystallographic artifact stemming from the phosphate buffer used in crystallization, as a phosphate ion is observed bound in the active site of the apoADC-7 structure.¹⁰ However, O2 phosphorylation is not observed in studies with the related class C β -lactamase AmpC in complexes with four of the same inhibitors bound, and AmpC also crystallizes in phosphate buffer, although at a higher pH (pH 8.6–8.8 vs pH 5 for ADC-7).¹⁹

An important feature in the design of the R1 BATSI is their ability to mimic the R1 amide found in β -lactam antibiotics, as well as the previously studied BATSI S02030. In both the ADC-7/S02030 complex¹⁰ and in the AmpC/cephalothin complex,²¹ the amide group forms hydrogen bonds with the side chains of Gln120 and Asn152, as well as the main chain carbonyl oxygen of Ser315. In this study, four of the BATSI replace the amide with a sulfonamide (Table 3). The X-ray crystal structures revealed that the sulfonamide formed hydrogen bonds in a similar fashion to Gln120 and Asn152, although it lacks the hydrogen bond with the main chain of Ser315 (Figures 4 and 5). Notably, the K_i values for all CR BATSI are in the nM range; these observations demonstrate that a sulfonamide is a successful, although not perfect, mimic of the β -lactam R1 amide group.¹⁰ The mode of binding to the sulfonamide was consistent with AmpC/CR167, in which both Gln120 and Asn152 interacted with the sulfonamide; however, the AmpC complexes with CR157, CR161, and CR192 showed Gln120 side chain adopting a conformation swung out from the

active site so that it no longer interacts with sulfonamides of these BATSIs.¹⁹ Alternatively, S06017 was designed to contain a triazole group in place of the R1 amide/sulfonamide. The triazole group, a known nonclassical amide bioisostere easily accessible by click-chemistry reaction, provides a chemical moiety from which numerous combinations of compounds can be engineered with relatively efficient synthesis.²² Indeed, the triazole forms hydrogen bonds with the conserved Gln120 and Asn152 residues, but not Ser315, seemingly to work as a mimic for the sulfonamide (Figure 4). However, microbiological studies indicated that this BATSI was the least efficient inhibitor, as it had the highest MIC and lowest DSA value for any of the five tested BATSIs (Table 2). In addition, kinetic studies revealed that S06017 exhibits the lowest binding affinity to ADC-7 ($K_i = 6.1 \mu\text{M}$) indicating that certain structural features are lacking in S06017, providing few interactions in the active site, thereby accounting for the overall poor binding affinity.

In the previous study of ADC-7 with S02030, a potential distal carboxylate binding site adjacent to the R1 group was proposed, with potential binding partners of Gln120 and Ser317.¹⁰ In this study, each of the BATSIs contained an extended R1 group terminating in either a carboxylate or a tetrazole, substituents that contain similar electronic and steric features. As proposed, the terminal substituent of all four CR BATSIs formed hydrogen bonds with the backbone atoms of Ser317 and Asn213, resulting in low K_i values for these inhibitors (Figure 4A–D). In the microbiological studies of the CR BATSIs, the Asn213Ala mutation causes a 2- to 4-fold increase in the MIC values. While the Asn213 interaction is via the main chain, it is possible that the change in side chain moves the backbone atoms enough to decrease H-bonding with the R1 carboxylate/tetrazole. The fifth BATSI, S06017, is distinguished by a shorter R1 group, and the carboxylate group is unable to reach the distal site to form interactions with Asn213 and Ser317 (Figure 4E). Instead, the carboxylate forms an ionic bond with the side chain of Arg340. However, even with the addition of this interaction with Arg340, as stated earlier, the S06017 has the lowest binding affinity to ADC-7. This would suggest that the ADC-7/BATSI interactions involving the distal active site residues, Ser317 and Asn213, serve to play a role in binding the inhibitor in ADC-7. Sequence alignment among ADC enzymes shows that Asn213 is completely conserved, whereas position 317 consists of serine (ADC-7), asparagine, or threonine; all of which have the potential to form interactions with the inhibitor via main chain and side chain hydrogen bonds.

The active site Arg340 is unique to the ADC enzymes among class C β -lactamases. While it has been previously shown to interact with the R2 carboxylate of S02030,¹⁰ as well as with the R1 carboxylate of S06017, it does show an interesting interaction with the CR192 BATSI. The only structural difference between the two inhibitors, CR157 and CR192, is the trifluoromethyl substituent on the phenyl ring of CR192, which resulted in a significant (almost 100-fold) increase in affinity for ADC-7 (Table 3, Figure 6). Both complexes have identical active site interactions, except the trifluoromethyl substituent on CR192 interacts with Arg340. This specific interaction has the potential to be either a Coulombic interaction or a hydrogen bond with the Arg340 acting as the donor and the fluorines acting as acceptors. Analysis of the interaction in all four monomers suggests that the center of the trifluoromethyl points at the carbon of the guanidinium group of Arg340. These two centers are within ionic bond distance (4.0 Å) and could be a Coulombic interaction with the

fluorines partial negative charges summing to a net negative charge.^{23–25} Regardless of whether it is involved in hydrogen bond or Coulombic interactions, the arginine is oriented at an angle toward the side of the C–F bonds which is consistent with more negative electron potential being located on the side of the fluorines in the C–F bonds.²⁶ Whether the interaction is hydrogen bonding or columbic, the structural data combined with kinetic studies reveal this interaction provides increased affinity down to the low nanomolar range (Table 3). In addition, the K_i was determined for the ADC-7/R340A mutant with CR192 (8.3 nM). This is ~20-fold weaker binding to CR192 than wild type ADC-7 (K_i of 0.45 nM), confirming the contribution of the R340 interaction to the overall binding affinity to CR192. Conversely, in a complex that lacks any interaction with R340 (ADC-7/CR161), the R340A mutation does not cause a significant decrease in the binding affinity to CR161 (K_i of 2.1 nM vs 7.8 nM for wild type ADC-7/CR161).

Microbiological studies indicate that the Arg340Ala does not affect the MIC for CR157, CR167, and CR161, which is consistent with the X-ray structural data showing that Arg340 does not interact with those BATSIs. The “anchoring” effect of the distal site interactions with BATSI is more relevant for the CR192 compound. The Arg340 mutation (Table 2), with the loss of the Arg340/CR192 trifluoromethyl interaction, does not result in an increase in MIC, suggesting that the distal site interaction is preserved (the MIC decreases from 2 to 0.5 $\mu\text{g}/\text{mL}$). Despite knowing that the Arg340Ala mutation lowers the binding affinity to CR192, ADC-7_{R340A} retains an overall tight binding affinity that does not appear to negatively impact the MIC results.

Finally, another interaction between ADC-7 and the CR BATSI that may contribute to the binding, as well as explain some of the differences in binding affinity, is the aryl interaction with Tyr222 and the aromatic rings of the inhibitors. Consistent with the interactions with these BATSI and the analogous residue of AmpC (Tyr221),¹⁹ the phenyl rings of CR157, CR161, and CR192 form edge-to-face π – π stacking at angles of 63°, 57°, and 58°, respectively, while the benzyl ring of CR167 forms parallel displaced π – π stacking at an angle of 18° (Figure 7).^{27,28} A potential reason for the different π – π conformation may be a result of the extra carbon linker observed in CR167, allowing an extra degree of rotational freedom. CR167 possesses a K_i of 160 nM, a minimum of 4-fold larger than the other K_i values, suggesting that edge-to-face π – π stacking may provide a higher affinity than parallel displaced, though this may also be attributed to other small differences in active site interactions. The structures of CR157, CR161, and CR192 are strikingly similar; yet, the inhibitors have varying affinities for ADC-7. Analysis of the X-ray crystal structures of these complexes cannot fully explain why replacing the aryl ring of CR157 with a pyridine ring in CR161 results in a 5-fold greater affinity for ADC-7. One potential reason is that, with the pyridine nitrogen pointing away from the Tyr222 aryl ring (CR161), the hydrogens on the opposite side of the pyridine ring have been shown to be more effective “ π –hydrogen bond donors” as compared to phenyl ring lacking a heteroatom (CR157).²⁹

Overall, this study provides insight into inhibitor recognition and design for ADC β -lactamases. Comparing the inhibitors, it is clear that optimizing an inhibitor for ADC-7 will include forming interactions with the distal carboxylate binding site, comprised of residues Asn213 and Ser317. From the kinetic studies, the edge-to-face π – π stacking is optimal for

greater affinity. One can observe the unique interaction between the trifluoromethyl and Arg340, and forming interactions with this residue provides higher affinity for ADC-7. Resulting from the previous ADC-7/S02030 complex and CR192 complex, the plasticity for varying interactions with Arg340 is possible. Further exploration into Arg340 interactions will be beneficial in further optimization of BATSI.

METHODS

Synthesis and Chemical Analysis

CR157, CR161, CR167, and CR192 were synthesized as previously described.¹⁹ The synthesis of S06017 was also previously described.²²

Disc Susceptibility Assays (DSAs) and Minimum Inhibitory Concentrations (MICs)

DSAs and MICs were performed as previously described¹⁰ and according to Clinical and Laboratory Standards Institute (CLSI) guidelines.³⁰ Bacterial cultures were grown overnight in Mueller-Hinton (MH) broth supplemented with 20 $\mu\text{g/mL}$ chloramphenicol to ensure maintenance of the β -lactamase plasmid in pBC SK (–) containing *Escherichia coli* strains. Liquid culture was then diluted using MH broth to a McFarland Standard ($\text{OD}_{600} = 0.224$). Bacteria were plated on MH agar, and a disc containing 10 μg of compound and 10 μg of ceftazidime was added. After an overnight incubation at 37 °C, zone sizes were measured and reported.

Susceptibility profiles (MICs) were determined by cation-adjusted MH agar dilution and liquid microdilution. We employed the *E. coli* construct in a uniform genetic background (*bla*ADC-7 was directionally cloned in pBC SK (–) phagemid vector under the control of a strong promoter). Site directed mutagenesis was performed at position Arg340 (for mutations to Ala and Lys) and Asn213 to Ala. A clinical strain *A. baumannii* M9, the multidrug resistant (MDR) strain from which *bla*ADC was initially cloned,⁸ was used as well. For the ceftazidime/BATSI combinations, the substrate concentrations were varied while the inhibitors were tested at a constant concentration of 4 $\mu\text{g/mL}$ according with the CLSI standards for β -lactamases inhibitors.

Protein Preparation and Purification

A construct containing amino acids D24-K383 of ADC-7 was expressed using a pET28a(+) plasmid and purified using a *m*-amino-phenylboronic acid resin (Sigma) as previously described.¹⁰ The concentration of ADC-7 was calculated using the A_{280} with an extinction coefficient of 46 300 $\text{M}^{-1} \text{cm}^{-1}$ calculated for the expressed residues, D24-K383, by the ProtParam tool on the ExPASy bioinformatics portal.³¹

ADC-7 X-ray Structure Determination

ADC-7 crystals were grown at room temperature via hanging drop vapor diffusion using the following conditions: ADC-7 (3 mg/mL) in 25% w/v polyethylene glycol (PEG) 1500 and 0.1 M succinate/ phosphate/glycine buffer at pH 5.0 (SPG buffer, Molecular Dimensions). Crystals were harvested from the drop using a nylon loop and soaked for 2 h in crystallization buffer containing 1 mM BATSI and subsequently cryocooled in liquid

nitrogen. In the case of CR161, 1 mM of CR161 was included in the initial crystallization buffer and allowed to cocrystallize with ADC-7. Data were measured from an individual crystal at LS-CAT sector (21-1D-D and 21-1D-F beamlines) at the Advanced Photon Source at Argonne National Laboratory (Argonne, IL). Images were indexed, integrated, and scaled with XDS.³² Molecular replacement was completed with Phaser³³ using the ADC-7 apo structure from *Acinetobacter baumannii* (4U0T) with waters and ions removed.¹⁰ Refinement was performed using Refmac5 in the CCP4 program suite.^{32,34} Repeated rounds of model building were completed in Coot.³⁵ The coordinates and structure parameters for the final ADC-7/BATSI complexes are available at the Protein Data Bank as 5WAC (CR157), 5WAD (CR161), 5WAE (CR167), 5WAF (CR192), and 5WAG (S06017).

Steady-State Kinetics

Competition kinetics were completed on a Cary 100 UV–vis spectrophotometer (Agilent Technologies). The K_i for the BATSI was calculated by measuring the steady-state initial velocities in the presence of a constant concentration of 2 nM enzyme with increasing concentration of inhibitor against the colorimetric indicator substrate, 60 μ M nitrocefin (NCF) in 10 mM phosphate-buffered saline (pH 7.4) as previously described.¹² In each assay, the measurements were taken after a 5 min preincubation of enzyme with BATSI. The average velocities (v_0) were then fitted to eq 1,

$$v_0 = v_u - \frac{v_u [I]}{K_{i(\text{observed})} + [I]} \quad (1)$$

where v_u represents the uninhibited turnover of NCF, $K_{i(\text{observed})}$ is the concentration of inhibitor that results in a 50% reduction of v_u , and $[I]$ is the concentration of inhibitor in the experiment. K_i values were also corrected for NCF affinity ($K_m = 21.2 \mu$ M) according to eq 2,

$$K_{i(\text{corrected})} = \frac{K_{i(\text{observed})}}{1 + \frac{[\text{NCF}]}{K_{m\text{NCF}}}} \quad (2)$$

Circular Dichroism (CD)

Thermal denaturation and stability CD experiments were performed using a Jasco J-815 spectrometer (Easton, MD) with a Peltier effect temperature controller (GE Healthcare, Piscataway, NJ) as previously described.¹⁰ Quartz cells with a 0.1 cm path length (Hellma, New York) were used for all experiments. Spectra were obtained with an ADC-7 concentration of 10 μ M. Compounds were tested at a concentration of 50 μ M to ensure that they do not interfere with the refraction of the light by the protein in the far UV spectrum. Thermal melting was performed between 20 and 80 °C with a heating rate of 2 °C/min. Raw equilibrium denaturation data, monitored by far-UV CD at 222 nm, were normalized to the fraction of denatured protein (f_u), and the data were used for calculations of melting

temperature T_m . To determine if the thermal denaturation of ADC-7 follows a two-state process, the sample was monitored for changes in tertiary structure in the near-UV region, at 270 nm (data not shown), as previously described by Beadle et al.³⁶ The melting for near-UV CD was performed using 30 $\mu\text{g/mL}$ ADC-7 and a heating rate of 2 $^{\circ}\text{C/min}$.

Acknowledgments

This work was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Department of Veterans Affairs Merit Review Program 1101BX001974, the Veterans Integrated Service Network 10 Geriatric Research, Education, and Clinical Center (VISN 10 GRECC), and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01 AI072219 (R.A.B.), as well as National Institutes of Health R15 AI094489 (R.A.P.). Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under Contract No. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). H.C.S. (MaryBeth Koeze Fellow) and A.L.V. were supported by the Student Summer Scholars Program in the Office of Undergraduate Research at GVSU.

ABBREVIATIONS

ADC	<i>Acinetobacter</i> -derived cephalosporinase
BLI	β -lactamase inhibitors
BATSI	boronic acid transition state inhibitor
NCF	nitrocefin
RMSD	root-mean-square deviation
MDR	multi-drug resistant
PDB	Protein Data Bank

References

1. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev.* 2010; 74(3):417–33. [PubMed: 20805405]
2. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis.* 2006; 43(Suppl 2):S49–S56. [PubMed: 16894515]
3. Perez F, Endimiani A, Bonomo RA. Why are we afraid of *Acinetobacter baumannii*? *Expert Rev Anti-Infect Ther.* 2008; 6(3):269–71. [PubMed: 18588489]
4. Perez F, Endimiani A, Ray AJ, Decker BK, Wallace CJ, Hujer KM, Ecker DJ, Adams MD, Toltzis P, Dul MJ, Windau A, Bajaksouzian S, Jacobs MR, Salata RA, Bonomo RA. Carbapenem-resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae* across a hospital system: impact of post-acute care facilities on dissemination. *J Antimicrob Chemother.* 2010; 65(8):1807–18. [PubMed: 20513702]
5. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2007; 51(10):3471–84. [PubMed: 17646423]
6. Wright MS, Haft DH, Harkins DM, Perez F, Hujer KM, Bajaksouzian S, Benard MF, Jacobs MR, Bonomo RA, Adams MD. New insights into dissemination and variation of the health care-associated pathogen *Acinetobacter baumannii* from genomic analysis. *mBio.* 2014; 5(1):e00963–13. [PubMed: 24449752]

7. Livermore DM. β -lactamase-mediated resistance and opportunities for its control. *J Antimicrob Chemother.* 1998; 41(Suppl 4):25–41.
8. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, Thomson JM, Anderson VE, Barlow M, Rice LB, Tenover FC, Bonomo RA. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7 β -lactamase: defining a unique family of class C enzymes. *Antimicrob Agents Chemother.* 2005; 49(7):2941–8. [PubMed: 15980372]
9. Tian GB, Adams-Haduch JM, Taracila M, Bonomo RA, Wang HN, Doi Y. Extended-spectrum AmpC cephalosporinase in *Acinetobacter baumannii*: ADC-56 confers resistance to cefepime. *Antimicrob Agents Chemother.* 2011; 55(10):4922–5. [PubMed: 21788456]
10. Powers RA, Swanson HC, Taracila MA, Florek NW, Romagnoli C, Caselli E, Prati F, Bonomo RA, Wallar BJ. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of *Acinetobacter baumannii*. *Biochemistry.* 2014; 53(48):7670–9. [PubMed: 25380506]
11. Drawz SM, Bonomo RA. Three decades of β -lactamase inhibitors. *Clin Microbiol Rev.* 2010; 23(1):160–201. [PubMed: 20065329]
12. Crompton IE, Cuthbert BK, Lowe G, Waley SG. β -lactamase inhibitors. The inhibition of serine β -lactamases by specific boronic acids. *Biochem J.* 1988; 251(2):453–459. [PubMed: 3135799]
13. Bou G, Santillana E, Sheri A, Beceiro A, Sampson JM, Kalp M, Bethel CR, Distler AM, Drawz SM, Pagadala SR, van den Akker F, Bonomo RA, Romero A, Buynak JD. Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of *Acinetobacter baumannii* OXA-24 carbapenemase. *J Am Chem Soc.* 2010; 132(38):13320–31. [PubMed: 20822105]
14. Pratt RF. Inhibition of a class C β -lactamase by a specific phosphonate monoester. *Science.* 1989; 246(4932):917–9. [PubMed: 2814513]
15. Wyrembak PN, Babaoglu K, Pelto RB, Shoichet BK, Pratt RF. O-aryloxycarbonyl hydroxamates: new β -lactamase inhibitors that cross-link the active site. *J Am Chem Soc.* 2007; 129(31):9548–9. [PubMed: 17628063]
16. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non- β -lactam β -lactamase inhibitors. *Curr Opin Microbiol.* 2011; 14(5):550–5. [PubMed: 21840248]
17. King AM, King DT, French S, Brouillette E, Asli A, Alexander JA, Vuckovic M, Maiti SN, Parr TR Jr, Brown ED, Malouin F, Strynadka NC, Wright GD. Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine- β -Lactamases and Penicillin-Binding Proteins. *ACS Chem Biol.* 2016; 11(4):864–8. [PubMed: 26731698]
18. Mosley JF 2nd, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections. *Pharmacy and Therapeutics (P&T).* 2016; 41(8):479–483. [PubMed: 27504064]
19. Eidam O, Romagnoli C, Dalmaso G, Barelier S, Caselli E, Bonnet R, Shoichet BK, Prati F. Fragment-guided design of subnanomolar β -lactamase inhibitors active in vivo. *Proc Natl Acad Sci U S A.* 2012; 109(43):17448–53. [PubMed: 23043117]
20. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. Structure-based optimization of cephalothin-analogue boronic acids as β -lactamase inhibitors. *Bioorg Med Chem.* 2008; 16(3):1195–205. [PubMed: 17997318]
21. Beadle BM, Trehan I, Focia PJ, Shoichet BK. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC β -lactamase. *Structure.* 2002; 10(3):413–24. [PubMed: 12005439]
22. Romagnoli C, Caselli E, Prati F. Synthesis of 1,2,3-triazol-1-yl-methaneboronic acids via click chemistry: an easy access to a new potential scaffold for protease inhibitors. *Eur J Org Chem.* 2015; 2015(5):1075–1083.
23. Chaudhari SR, Mogurampelly S, Suryaprakash N. Engagement of CF₃ group in N-H...F-C hydrogen bond in the solution state: NMR spectroscopy and MD simulation studies. *J Phys Chem B.* 2013; 117(4):1123–9. [PubMed: 23289872]
24. Murray JS, Lane P, Politzer P. Expansion of the sigma-hole concept. *J Mol Model.* 2009; 15(6):723–9. [PubMed: 19082643]
25. Wang C, Guan L, Danovich D, Shaik S, Mo Y. The origins of the directionality of noncovalent intermolecular interactions. *J Comput Chem.* 2016; 37(1):34–45. [PubMed: 26010349]

26. Sirimulla S, Bailey JB, Vegesna R, Narayan M. Halogen interactions in protein-ligand complexes: implications of halogen bonding for rational drug design. *J Chem Inf Model*. 2013; 53(11):2781–91. [PubMed: 24134121]
27. Egli M, Tereshko V, Mushudov GN, Sanishvili R, Liu X, Lewis FD. Face-to-face and edge-to-face pi-pi interactions in a synthetic DNA hairpin with a stilbenediether linker. *J Am Chem Soc*. 2003; 125(36):10842–9. [PubMed: 12952463]
28. McGaughey GB, Gagne M, Rappe AK. pi-Stacking interactions. Alive and well in proteins. *J Biol Chem*. 1998; 273(25):15458–15463. [PubMed: 9624131]
29. Hohenstein EG, Sherrill CD. Effects of heteroatoms on aromatic pi-pi interactions: benzene-pyridine and pyridine dimer. *J Phys Chem A*. 2009; 113(5):878–86. [PubMed: 19132847]
30. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. Vol. 27. Clinical and Laboratory Standards Institute; Wayne, Pennsylvania: 2007. p. M100-S17
31. Perichon B, Goussard S, Walewski V, Krizova L, Cerqueira G, Murphy C, Feldgarden M, Wortman J, Clermont D, Nemec A, Courvalin P. Identification of 50 class D β -lactamases and 65 *Acinetobacter*-derived cephalosporinases in *Acinetobacter* spp. *Antimicrob Agents Chemother*. 2014; 58(2):936–49. [PubMed: 24277043]
32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr, Sect D: Biol Crystallogr*. 1997; 53(3):240–255. [PubMed: 15299926]
33. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007; 40(4):658–674. [PubMed: 19461840]
34. CCP4 Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr, Sect D: Biol Crystallogr*. 1994; 50(5):760–763. [PubMed: 15299374]
35. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. *Acta Crystallogr, Sect D: Biol Crystallogr*. 2004; 60:2126–2132. [PubMed: 15572765]
36. Beadle BM, McGovern SL, Patera A, Shoichet BK. Functional analyses of AmpC β -lactamase through differential stability. *Protein Sci*. 1999; 8(9):1816–1824. [PubMed: 10493583]
37. The PyMOL Molecular Graphics System, Version 1.3. Schrödinger, LLC; New York: 2010.

Figure 1.

Structural differences between β -lactams, BLIs, and BATSIs. (A) The cephalosporin, cephalothin, with the R1 and R2 side chains indicated. (B) BLI, sulbactam. (C) S02030 BATSI containing both R1 and R2 groups. (D) CR192 BATSI containing only an R1. (E) CR192 bound in tetrahedral molecular geometry to catalytic serine, with labeled O1 and O2 of the boronic acid.

Figure 2.

Thermal denaturation curves of ADC-7 enzyme and of the complexes between ADC-7 and boronic acid compounds. All compounds thermodynamically stabilize the enzyme. The largest variation of melting temperature (T_m) is observed for CR192. The compound stabilizes the enzyme from a T_m of $\approx 61^{\circ}\text{C}$ to almost 70°C .

Figure 3.

Stereoview of the various BATSIs covalently bound to catalytic Ser-64 with their respective electron density maps. $F_o - F_c$ omit maps for the inhibitors, contoured at 3.0σ , are displayed as a gray cage surrounding the model. (A) CR157 (carbon atoms are colored green). (B) CR161 (carbons white). (C) CR167 (carbons magenta). (D) CR192 (carbons cyan). (E) S06017 (carbons gray). This and all subsequent figures are generated with PyMOL.³⁷

Figure 4.

Stereoview of the ADC-7 active site in complex with various BATSIs. The carbon atoms of the active site residues and inhibitors are colored as follows. (A) ADC-7/CR157 (green). (B) ADC-7/CR161 (white). (C) ADC-7/CR167 (magenta). (D) ADC-7/CR192 (cyan). (E) ADC-7/S06017 (gray). Hydrogen bonding interactions are shown as yellow dashed lines, and cumbic interactions are shown as magenta dashed lines. Water molecules are shown as red spheres. The colors are as follows: oxygens, red; nitrogens, blue; boron, pale pink; fluorines, white; phosphorus, orange.

Figure 5.
Superposition of ADC-7 in complex with three inhibitors: CR157 (green), CR161 (white), and CR192 (cyan).

Figure 6.
Stereoview of CR192 forming a potential columbic interaction between positively charged Arg340 and a net negative charge trifluoromethyl substituent.

Figure 7. Interactions of Tyr222 with BATSI. (A) CR167 (magenta) forming parallel displaced π - π stacking with Tyr222 and (B) CR157 (green), (C) CR161 (white), and (D) CR192 (cyan) forming edge-to-face π - π stacking with Tyr 222.

Table 1Disc Susceptibility Assays (DSAs)^a

	<i>E. coli</i> DH10B <i>bla</i> _{ADC-7}	<i>E. coli</i> DH10B <i>bla</i> _{ADC-7,N213A}	M9 clinical isolates
no antibiotic	6	6	6
CAZ – 10 µg	12	11	6
CAZ + 10 µg achiral cephalothin	17	16	8
CAZ + 10 µg S06017	15	15	6
CAZ + 10 µg CR167	22	18	12
CAZ + 10 µg CR157	24	17	15
CAZ + 10 µg CR161	26	20	16
CAZ + 10 µg CR192	20	15	14

^aUnits are in mm.

Table 2

MIC Values ($\mu\text{g/mL}$) in Combination with 4 $\mu\text{g/mL}$ BATSI Compound

strain	CAZ	CAZ S06017	CAZ CR167	CAZ CR157	CAZ CR161	CAZ CR192	CAZ achiral cephalothin
<i>E. coli</i> DH10B	1	0.5	0.5	0.5	0.5	0.5	0.5
<i>E. coli</i> DH10B pBCSK, <i>bla</i> _{ADC-7}	64	16	1	0.5	2	32	32
<i>E. coli</i> DH10B pBCSK, <i>bla</i> _{ADC-7} , R340A	32	16	2	0.5	1	0.5	32
<i>E. coli</i> DH10B pBCSK, <i>bla</i> _{ADC-7} , R340K	32	16	4	1	2	32	32
<i>E. coli</i> DH10B pBCSK, <i>bla</i> _{ADC-7} , N213A	32	16	4	2	1	32	32
<i>A. baumannii</i> M9	>64	16	16	8	8	8	32

Table 3Kinetic Parameters and Chemical Structures for the Various BATSIs^a

Compound	Chemical Structure	K_i	T_m [°C]
CR167		160	+ 2
CR157		38	+ 4
CR161		7.8	+ 5
CR192		0.45	+ 9
S06017		6,110	+ 2

^aThe variation in melting temperature T_m between $T_m^{ADC-7} = 61 \pm 1$ °C and in complex with the boronic acid compounds shows an increase in the complex stability upon binding.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4

Crystallographic Summary for the ADC-7/Inhibitor Complexes

	ADC-7/CR167	ADC-7/CR157	ADC-7/CR161	ADC-7/CR192	ADC-7/S06017
cell constants (Å; deg)	<i>a</i> = 88.79 <i>b</i> = 81.05 <i>c</i> = 105.06 β = 113.45	<i>a</i> = 88.35 <i>b</i> = 80.67 <i>c</i> = 104.98 β = 113.42	<i>a</i> = 89.27 <i>b</i> = 81.47 <i>c</i> = 105.91 β = 112.50	<i>a</i> = 89.02 <i>b</i> = 81.28 <i>c</i> = 106.38 β = 112.64	<i>a</i> = 88.67 <i>b</i> = 80.90 <i>c</i> = 105.34 β = 113.36
space group	P2 ₁	P2 ₁	P2 ₁	P2 ₁	P2 ₁
resolution (Å)	1.80 (1.81–1.80) ^a	2.06 (2.07–2.06) ^a	2.09 (2.10–2.09) ^a	2.03 (2.04–2.03) ^a	1.93 (1.94–1.93) ^a
unique reflections	124 952	82 849	82 578	90 002	99 952
total observations	468 752	307 282	309 158	376 247	376 640
<i>R</i> _{merge} (%)	5.9 (66.2)	7.0 (55.3)	8.4 (66.6)	10.4 (65.2)	7.8 (63.2)
completeness (%) ^b	99.4 (99.2)	98.9 (99.0)	99.3 (99.8)	99.5 (99.5)	97.4 (95.9)
$\langle I/\sigma \rangle$	15.1 (2.1)	11.6 (2.3)	11.5 (2.0)	8.8 (2.2)	10.8 (2.1)
resolution range for refinement (Å)	50.00–1.80	48.17–2.06	50.00–2.09	50.00–2.03	50.00–1.93
number of protein residues	1422	1418	1406	1422	1424
number of water molecules	586	188	370	349	389
RMSD bond lengths (Å)	0.019	0.015	0.015	0.016	0.017
RMSD bond angles (deg)	1.952	1.745	1.790	1.832	1.864
<i>R</i> -factor (%)	18.3	20.3	21.4	21.5	18.6
<i>R</i> _{free} (%) ^c	23.2	26.4	28.6	27.7	24.7
average B-factor, protein atoms (Å ²)	33.84	44.37	39.03	41.32	37.46
average B-factor, inhibitor atoms (Å ²)	36.35	52.64	39.61	34.87	46.19
average B-factor, water molecules (Å ²)	35.01	38.54	35.45	36.53	36.17

^aValues in parentheses are for the highest resolution shell.^bFraction of theoretically possible reflections observed.^c*R*_{free} was calculated with 5% of reflections set aside randomly.